During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Ajai Chari, Icahn School of Medicine at Mount Sinai, New York, US, about G protein-coupled receptor family C group 5 member D (GPRC5D) as a promising target for multiple myeloma.
GPRC5D is an orphan receptor overexpressed in mammalian myeloma cells, making it an attractive therapeutic target. Chari reports the promising results of a phase I, first-in-human study, evaluating a first-in-class agent targeting GPRC5D in patients with relapsed and/or refractory multiple myeloma.